摘要
目的探讨沙利度胺联合紫杉醇加顺铂方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选择84例老年晚期NSCLC患者为研究对象,根据入院时间分为观察组和对照组,各42例。对照组给予紫杉醇加顺铂(TP)方案化疗,观察组给予沙利度胺联合TP方案治疗。观察2组临床疗效、肿瘤标志物、不良反应等指标。结果观察组疾病控制率为85.71%,明显高于对照组的64.29%(χ~2=5.143,P<0.05);观察组无进展生存时间、总生存时间均明显长于对照组(t=6.689,2.754,P<0.05)。2组患者血清癌胚抗原(CEA)、癌抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)水平差异均有统计学意义(t=16.646,15.125,16.428,P<0.05)。观察组恶心呕吐(40.48%)明显低于对照组(76.19%),便秘、乏力或嗜睡发生率明显高于对照组(χ~2=11.020,6.158,4.414,P<0.05);2组白细胞减少、血小板减少、血红蛋白减少、周围神经毒性等发生率比较,差异无统计学意义(P>0.05)。结论沙利度胺联合紫杉醇加顺铂方案治疗晚期非小细胞肺癌有助于降低患者血清肿瘤标志物表达水平,提高临床疗效,但应预防便秘、乏力或嗜睡等不良反应。
Objective To study the clinical effects of thalidomide combined with paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods 84 patients with senile advanced NSCLC were selected and divided into the observation group and the control group according to their admission time,with 42 cases in each group.The control group were treated with paclitaxel and cisplatin （TP）regimen chemotherapy and the observation group were treated with thalidomide combined with TP regimen.Indicators including clinical effects,tumor markers and untoward effects of the 2 groups were observed. Results Disease control rate of the observation group was 85.71%,which was apparently higher than that of the control group,64.29% （χ^2=5.143, P 〈0.05）;progression-free survival,overall survival time of the observation group were longer than those of the control group （ t =6.689,2.754, P 〈0.05）;serum carcino-embryonic antigen （CEA）,cancer antigen （CA125）,level of cytokeratin 19 fragments （CYFRA21-1）of the 2 groups had significant difference （ t =16.646,15.125,16.428, P 〈 0.05 ）;nausea and vomiting rate of the observation group was 40.48%,which was apparently lower than that of the control group, 76.19 %;the occurrence rates of constipation,being feeble or somnolence of the observation group was apparently higher than those of the control group（χ^2=11.020,6.158,4.414, P 〈0.05）;leukopenia,thrombocytopenia,hemoglobin decrease and surrounding neurovirulence of the 2 groups were not statistically different （ P 〉0.05）. Conclusion Thalidomide combined with paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer is conductive to lowering the expression levels of tumor markers,and can enhance the clinical effects.However,untoward effects such as constipation,being feeble and somnolence should be prevented.
作者
韦华军
钟亮
曾湖
蔡茂德
WEI Huajun;ZHONG Liang;ZENG Hu(The People＇s Hospital of Gaozhou,Gaozhou,52520)
出处
《实用癌症杂志》
2018年第7期1165-1168,共4页
The Practical Journal of Cancer
关键词
晚期非小细胞肺癌
沙利度胺
紫杉醇
顺铂
肿瘤标志物
Advanced non-small cell lung cancer
Thalidomide
Paclitaxel
Cisplatin
Tumor marker
